Pliant Therapeutics (PLRX) 2024 Wells Fargo Healthcare Conference summary

Key scientific insights and clinical progress

• Targeting integrins alpha V beta 6 and alpha V beta 1 enables selective TGF-beta inhibition in IPF, avoiding systemic toxicity and showing promise in other fibrotic lung diseases.

• Biomarker data support the use of Bexotograst in IPF and other interstitial lung diseases, with integrin beta 6 levels predicting disease progression.

• Over 700 participants have been dosed with Bexotograst, with no dose-related serious adverse events and a favorable safety profile up to 40 weeks.

• Phase IIa INTEGRIS-IPF study demonstrated dose-dependent efficacy, with significant improvements in FVC, reduced fibrosis progression, and improved cough at higher doses.

• Collagen PET studies showed decreased collagen deposition with Bexotograst, supporting its anti-fibrotic mechanism.

Clinical development and trial design

• BEACON-IPF is a seamless phase IIb/III trial, designed to identify optimal dosing and serve as a potential registration study for IPF.

• Enrollment is on track for full completion in Q1 next year, with strong momentum in Europe and a target of 360 patients.

• The trial includes at least 30% of patients not on background therapy to assess monotherapy potential and aims for broad label applicability.

• Secondary endpoints include time to disease progression, imaging (QLF), and patient-reported outcomes to capture quality of life improvements.

• Adaptive design allows for sample size adjustments in phase III based on phase IIb results, aiming to de-risk the program.

Competitive landscape and commercial strategy

• Bexotograst is positioned as a pure anti-fibrotic with a strong safety and efficacy profile, differentiating it from competitors with tolerability issues.

• The market is expected to grow from $4 billion to $9–10 billion over the next decade, with opportunities to treat patients earlier and for longer durations.

• Expansion into progressive pulmonary fibrosis (PPF) and other ILDs is under consideration, with lifecycle management and phase IV planning underway.

• PSC program is deprioritized due to regulatory uncertainty and capital allocation, with focus remaining on IPF and pulmonary indications.

• Oncology and muscular dystrophy programs are in early stages, with plans to partner oncology and further explore the muscular mechanism before phase I.